Tri­fec­ta of clin­i­cal stage biotechs un­veil IPO plans, brav­ing Wall Street's coro­n­avirus pan­ic

Coro­n­avirus fears pre­cip­i­tat­ed a rout on glob­al stock prices on Mon­day, but three clin­i­cal-stage biotechs are sol­dier­ing on with plans to make pub­lic de­buts. The biggest is Zen­tal­is Phar­ma­ceu­ti­cals — which is gun­ning for a $100 mil­lion IPO, three months af­ter an $85 mil­lion round of fi­nanc­ing.

Found­ed in late 2014, the on­col­o­gy com­pa­ny emerged out of stealth in late 2019 with the Se­ries C round. So far the com­pa­ny has raised about $162 mil­lion in gross pro­ceeds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER